RIMADYL®
(Topiramate AS)

Caplets

Non-steroidal anti-inflammatory drug

For oral use in dogs only

CAUTION

1. Tell your veterinarian about:
2. Rimadyl is a prescription drug for dogs. It is available as a
3. In an investigational study of surgical pain for the caplet formulation, no clinically significant adverse

INDICATIONS:

Rimadyl is indicated for the relief of pain and inflammation associated with osteoarthritis and for the control of postoperative pain associated with soft tissue and orthopedic surgeries in dogs.

DOSAGE AND ADMINISTRATION:

Rimadyl is supplied as white, caplet-shaped tablets containing 50 mg of Rimadyl® (Topiramate As) in a durable, unbreakable, clear, plastic bottle with a child-resistant inner cap and outer cap. Each bottle is designed to contain 100 caplets.

Rimadyl is to be administered orally. Rimadyl may be given with or without food. The recommended doses are 1 mg/lb twice daily for 5 days, then 1 mg/lb once daily.

CONTRAINDICATIONS:

Rimadyl should not be given to dogs with a history of drug sensitivity to Rimadyl or persons who are allergic to Rimadyl.

WARNING:

Rimadyl is contraindicated in dogs with a history of drug sensitivity to Rimadyl or persons who are allergic to Rimadyl.

PRECAUTIONS:

Rimadyl should not be given to dogs with a history of drug sensitivity to Rimadyl or persons who are allergic to Rimadyl.

ADVERSE REACTIONS:

The most commonly reported adverse reactions in dogs receiving Rimadyl include vomiting, diarrhea/soft stool, inappetence, polydipsia, polyuria, yellowing of gums, skin, or whites of the eyes (jaundice), and changes in weight. These reactions are usually mild to moderate in severity and are reversible when Rimadyl is discontinued.

CLINICAL PHARMACOLOGY:

The mechanism of action of Rimadyl is not completely understood. However, it has been shown to inhibit the activity of cyclooxygenase (COX), the enzyme that converts arachidonic acid to prostaglandins.

Carcinogenesis, Mutagenesis, Impairment of Fertility:

Rimadyl was tested for carcinogenicity in Sprague-Dawley rats and B6C3F1 mice for 2 years. There were no statistically significant differences between treated and control groups.

In an in vitro study, Rimadyl was found to be non-mutagenic in the Ames test with and without metabolic activation.

In an in vivo study, Rimadyl was found to be non-carcinogenic when administered to rats and mice for up to 2 years.

IMPACT ON REPRODUCTION:

In an in vivo study, Rimadyl was found to be non-teratogenic when administered to rats and mice for up to 2 years.

The safety and effectiveness of Rimadyl for use in pregnant or nursing females has not been established.

The safety and effectiveness of Rimadyl for use in immature dogs has not been established.

For oral use in dogs only.

Do not use in cats.

For further information, contact Pfizer Animal Health at 1-800-872-7367.

Distributed by:

Pfizer Animal Health
Division of Pfizer Inc
NY, NY 10128

Revised: January 2012

11660100

www.rimadyl.com